Biotech and Pharmaceuticals Pharmaceuticals

  • I don't often write about micro caps, but given that the broader topic is bioterrorism and specifically something that the whole country was on pins and needles about not too long ago, I'm making an exception.

  • Monday will be a big day for the biotechnology company Celgene. At 3:45p ET, the embargo will apparently lift on new data for its drug Revlimid in an earlier stage of the blood cancer known as multiple myeloma.

  • microscope_200.jpg

    Normally things tend to slow down a bit between Thanksgiving and New Year's Day. But this week alone we've already seen two biopharma partnership deals in as many days. First Pfizer and Protalix and now AstraZeneca and Targacept.

  • Pfizer

    Pfizer today announced it's paying what amounts to chump change (a total of $115 million over time) for the rights to a biotech drug to treat a rare disease. And as I write this, investors are rewarding the world's biggest drug company by making its stock the biggest percentage gainer among the Dow 30.

  • Pfizer headquarters in New York City.

    Genzyme, the biotechnology company already reeling from problems manufacturing its drugs for rare diseases, will soon have a formidable new competitor — the pharmaceutical giant Pfizer.

  • There will be a short-term pullback after Thanksgiving in stock markets and there is a 50 percent chance that the US economy will double-dip, according to Paul Schatz, president of Heritage Capital.

  • swine_flu_needle_200.jpg

    For the second time in three weeks I'm at a flu vaccine manufacturing plant today. Construction isn't finished on the Novartis site yet, but nonetheless they're doing the formal ribbon-cutting ceremony here in Holly Springs, NC this afternoon.

  • With the health care debate continuing, how can investors make money in the sector? Barbara Ryan, managing director and senior pharmaceuticals analyst at Deutsche Bank Securities, and Charles Boorady, health care providers analyst at Citigroup, shared their insights.

  • In U.S. President Barack Obama's speech to Asia-Pacific leaders at the APEC Summit in Singapore over the weekend, he highlighted the importance of a strong China economy in the context of global growth.

  • Earlier this week I reported that Dr. Allen Taylor who ran the Abbott vs. Merck cholesterol drug study, which Abbott's drug Niaspan won, would only say that ABT has paid him more than $10,000 in lecture and consulting fees. But he wouldn't be any more specific than that.

  • VVUS this morning unveiled positive late-stage test results on the ED pill. The company touts that it takes effect in less than 30 minutes and it's out of your system within six hours or so.

  • In U.S. President Barack Obama's speech to Asia-Pacific leaders at the APEC Summit in Singapore over the weekend, he highlighted the importance of a strong China economy in the context of global growth.

  • When I do an interview with a clinical trial investigator I typically try to take care of what I call the "housekeeping" at the beginning or end.

  • Live TV is best when things are happening and news is breaking right now. It's immediate and often, hopefully, more compelling.

  • pills_prescription_200.jpg

    Even as drug makers promise to support Washington’s health care overhaul by shaving $8 billion a year off the nation’s drug costs after the legislation takes effect, the industry has been raising its prices at the fastest rate in years, reports the New York Times.

  • Merck

    For top analysts from investment banks, including JPMorgan  and Credit Suisse , or some of their minions, the destination is a cardiology conference where on Monday morning medical researchers are expected to present a study with potentially significant implications for multibillion-dollar cholesterol medications from the drug giant Merck.

  • A man walks past a sign for a Pfizer facility in the Fort Trumbull area of New London, Connecticut.

    Pfizer said it would pull 1,400 jobs out of New London within two years and move most of them a few miles away to a campus it owns in Groton, Conn., as a cost-cutting measure. It would leave behind the city’s biggest office complex and an adjacent swath of barren land that was cleared of dozens of homes to make room for a hotel, stores and condominiums that were never built.

  • It doesn't always happen, but there is a common to-and-fro, push-and-pull, back-and-forth or whatever you want to call it between reporters and corporate PR folks. I don't particularly like that part of my job, but sometimes it just comes with the territory. I've got my job to do and they've got theirs. I get it.

  • Twitter

    Today starts a two-day FDA public hearing in Washington, DC on biopharma and social media. I decided not to go because talking heads in a meeting room just don't make for good TV. And this is just the first step in what is no doubt going to be a very long, involved policy-making process. But as it turns out, it looks like it might have been futile for me to try to attend anyway.

  • swine_flu_needle_200.jpg

    When I went to the FDA's Web site today I was surprised to see on the homepage a link to a letter written by Commissioner Dr. Peggy Hamburg. It's addressed to "Dear Healthcare Professional" aka a "Dear Doctor letter." That's a common type of communication from the agency and/or companies to the medical community, usually when they've got bad news to pass along about a drug or device. It's pretty rare for the commish to write one.